Prime Medicine, Inc. (PRME)
Data as of , from SEC Form 4 filings.
No open-market insider trades (90d)Watch PRME
See up to 3 months of PRME. The 7-day demo opens the 1M and 3M ranges and puts PRME on your watchlist.
Start 7-day demoLatest PRME insider trades
- GV 2021 GP, L.L.C.Open-market purchase$4.95M
Robert Nelsen - DirectorOpen-market purchase$10.00M
About Prime Medicine, Inc. (PRME)
Prime Medicine, Inc. is an SEC registrant, filing under CIK 0001894562, classified as biological products (no diagnostic substances). We track it alongside the rest of the Health Care sector.
PRME Form 4 activity by transaction type, last 90 days
No Form 4 activity for PRME in the last 90 days.
PRME insider transactions (Form 4)
7430 Form 4 filings on record, the earliest from Oct 10, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| David P. Schenkein - Director | Grant or award | Stock Option (right to buy) | 75,000 | $0.00 | - | |
| Jeffrey D. Marrazzo - Director | Grant or award | Stock Option (right to buy) | 75,000 | $0.00 | - | |
| Robert Nelsen - Director | Grant or award | Stock Option (right to buy) | 75,000 | $0.00 | - | |
| Michael Aaron Kelly - Director | Grant or award | Stock Option (right to buy) | 75,000 | $0.00 | - | |
 Kaye I. Foster-Cheek - Director | Grant or award | Stock Option (right to buy) | 75,000 | $0.00 | - | |
 Wendy Chung - Director | Grant or award | Stock Option (right to buy) | 75,000 | $0.00 | - | |
 Thomas Cahill - Director | Grant or award | Stock Option (right to buy) | 75,000 | $0.00 | - | |
 Svetlana Ni Makhni - Officer | Grant or award | Stock Option (right to buy) | 800,000 | $0.00 | - | |
| Allan Reine - Officer | Grant or award | Stock Option (right to buy) | 1,300,000 | $0.00 | - | |
| Ann L. Lee - Officer | Grant or award | Stock Option (right to buy) | 375,000 | $0.00 | - | |
| Carman Alenson - Officer | Grant or award | Stock Option (right to buy) | 140,000 | $0.00 | - | |
| GV 2021 GP, L.L.C. | Open-market purchase | Common Stock | 1,500,000 | $3.30 | $4.95M | |
| Robert Nelsen - Director | Open-market purchase | Common Stock | 3,030,300 | $3.30 | $10.00M | |
| ARCH Venture Partners XII, LLC - 10% Owner | Open-market purchase | Common Stock | 3,030,300 | $3.30 | $10.00M | |
| ARCH Venture Partners X, LLC - 10% Owner | Open-market purchase | Common Stock | 3,030,300 | $3.30 | $10.00M | |
| Wendy Chung - Director | Derivative | Stock Option (right to buy) | 13,510 | - | - | |
| Wendy Chung - Director | Grant or award | Stock Option (right to buy) | 13,510 | - | - | |
| Wendy Chung - Director | Derivative | Stock Option (right to buy) | 9,006 | - | - | |
| Wendy Chung - Director | Grant or award | Stock Option (right to buy) | 9,006 | - | - | |
| Wendy Chung - Director | Derivative | Stock Option (right to buy) | 39,062 | - | - | |
| Wendy Chung - Director | Grant or award | Stock Option (right to buy) | 39,062 | - | - | |
| Wendy Chung - Director | Derivative | Stock Option (right to buy) | 45,000 | - | - | |
| Wendy Chung - Director | Grant or award | Stock Option (right to buy) | 45,000 | - | - | |
| Thomas Cahill - Director | Derivative | Stock Option (right to buy) | 39,062 | - | - | |
| Thomas Cahill - Director | Grant or award | Stock Option (right to buy) | 39,062 | - | - | |
| Thomas Cahill - Director | Derivative | Stock Option (right to buy) | 45,000 | - | - | |
| Thomas Cahill - Director | Grant or award | Stock Option (right to buy) | 45,000 | - | - | |
| Michael Aaron Kelly - Director | Derivative | Stock Option (right to buy) | 13,510 | - | - | |
| Michael Aaron Kelly - Director | Grant or award | Stock Option (right to buy) | 13,510 | - | - | |
| Michael Aaron Kelly - Director | Derivative | Stock Option (right to buy) | 9,006 | - | - | |
| Michael Aaron Kelly - Director | Grant or award | Stock Option (right to buy) | 9,006 | - | - | |
| Michael Aaron Kelly - Director | Derivative | Stock Option (right to buy) | 39,062 | - | - | |
| Michael Aaron Kelly - Director | Grant or award | Stock Option (right to buy) | 39,062 | - | - | |
| Michael Aaron Kelly - Director | Derivative | Stock Option (right to buy) | 45,000 | - | - | |
| Michael Aaron Kelly - Director | Grant or award | Stock Option (right to buy) | 45,000 | - | - | |
| Ann L. Lee - Officer | Derivative | Stock Option (right to buy) | 180,995 | - | - | |
| Ann L. Lee - Officer | Grant or award | Stock Option (right to buy) | 180,995 | - | - | |
| Ann L. Lee - Officer | Derivative | Stock Option (right to buy) | 180,995 | - | - | |
| Ann L. Lee - Officer | Grant or award | Stock Option (right to buy) | 180,995 | - | - | |
| Allan Reine - Officer | Derivative | Stock Option (right to buy) | 850,000 | - | - | |
| Allan Reine - Officer | Grant or award | Stock Option (right to buy) | 850,000 | - | - | |
| Carman Alenson - Officer | Derivative | Stock Option (right to buy) | 16,083 | - | - | |
| Carman Alenson - Officer | Grant or award | Stock Option (right to buy) | 16,083 | - | - | |
| Carman Alenson - Officer | Derivative | Stock Option (right to buy) | 90,498 | - | - | |
| Carman Alenson - Officer | Grant or award | Stock Option (right to buy) | 90,498 | - | - | |
| Carman Alenson - Officer | Derivative | Stock Option (right to buy) | 6,254 | - | - | |
| Carman Alenson - Officer | Grant or award | Stock Option (right to buy) | 6,254 | - | - | |
| Carman Alenson - Officer | Derivative | Stock Option (right to buy) | 90,498 | - | - | |
| Carman Alenson - Officer | Grant or award | Stock Option (right to buy) | 90,498 | - | - | |
| Jeffrey D. Marrazzo - Director | Derivative | Stock Option (right to buy) | 92,000 | - | - | |
| Jeffrey D. Marrazzo - Director | Grant or award | Stock Option (right to buy) | 92,000 | - | - | |
| Jeffrey D. Marrazzo - Director | Derivative | Stock Option (right to buy) | 250,000 | - | - | |
| Jeffrey D. Marrazzo - Director | Grant or award | Stock Option (right to buy) | 250,000 | - | - | |
| Jeffrey D. Marrazzo - Director | Derivative | Stock Option (right to buy) | 45,000 | - | - | |
| Jeffrey D. Marrazzo - Director | Grant or award | Stock Option (right to buy) | 45,000 | - | - | |
| David P. Schenkein - Director | Derivative | Stock Option (right to buy) | 39,062 | - | - | |
| David P. Schenkein - Director | Grant or award | Stock Option (right to buy) | 39,062 | - | - | |
| David P. Schenkein - Director | Derivative | Stock Option (right to buy) | 45,000 | - | - | |
| David P. Schenkein - Director | Grant or award | Stock Option (right to buy) | 45,000 | - | - | |
| Kaye I. Foster-Cheek - Director | Derivative | Stock Option (right to buy) | 13,510 | - | - | |
| Kaye I. Foster-Cheek - Director | Grant or award | Stock Option (right to buy) | 13,510 | - | - | |
| Kaye I. Foster-Cheek - Director | Derivative | Stock Option (right to buy) | 9,006 | - | - | |
| Kaye I. Foster-Cheek - Director | Grant or award | Stock Option (right to buy) | 9,006 | - | - | |
| Kaye I. Foster-Cheek - Director | Derivative | Stock Option (right to buy) | 39,062 | - | - | |
| Kaye I. Foster-Cheek - Director | Grant or award | Stock Option (right to buy) | 39,062 | - | - | |
| Kaye I. Foster-Cheek - Director | Derivative | Stock Option (right to buy) | 45,000 | - | - | |
| Kaye I. Foster-Cheek - Director | Grant or award | Stock Option (right to buy) | 45,000 | - | - | |
| David R. Liu - 10% Owner | Open-market purchase | Common Stock | 21,000 | $2.52 | $53K | |
| Robert Nelsen - Director | Grant or award | Stock Option (right to buy) | 55,000 | $0.00 | - | |
| Allan Reine - Officer | Grant or award | Stock Option (right to buy) | 75,000 | $0.00 | - | |
| Richard Brudnick - Officer | Grant or award | Stock Option (right to buy) | 19,300 | $0.00 | - | |
| Keith Michael Gottesdiener - Officer | Grant or award | Stock Option (right to buy) | 100,000 | $0.00 | - | |
| Keith Michael Gottesdiener - Officer | Gift | Common Stock | 226,925 | $0.00 | - | |
| Keith Michael Gottesdiener - Officer | Gift | Common Stock | 226,925 | $0.00 | - |
Item 2.02, 9.01
Item 8.01
Item 5.07
Item 2.02, 9.01
PRME insider trading FAQ
What is the latest insider trade for PRME?
Prime Medicine, Inc. (PRME) has filed no insider reports in the last 90 days. The most recent on record is dated 2026-06-08. The full record for PRME runs to 30 Form 4 filings, the earliest from 2024-10-10. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying PRME stock?
No insider purchases of PRME were filed in the last 90 days. 5 purchases are on record for this company.
How many insiders are selling PRME stock?
No insider sales of PRME were filed in the last 90 days.
Where can I see PRME SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects PRME Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - David P. Schenkein view on EDGAR
- - Jeffrey D. Marrazzo view on EDGAR
- - Robert Nelsen view on EDGAR
- - Michael Aaron Kelly view on EDGAR
- - Kaye I. Foster-Cheek view on EDGAR
- - Wendy Chung view on EDGAR
- - Thomas Cahill view on EDGAR
- - Svetlana Ni Makhni view on EDGAR
- - Allan Reine view on EDGAR
Related companies with recent insider activity
Learn more
- What the Form 4 transaction codes mean
- Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
- Insider activity in Health Care
- Where PRME's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow PRME with a 7-day demo
- PRME on your watchlist
- Every PRME Form 4 filing on record
- Up to 3 months of PRME price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
